TOP TEN perturbations for 39378_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39378_at
Selected probe(set): 208946_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39378_at (208946_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-1.9215317Number of Samples:2 / 2
| Experimental | ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted). | |
| Control | ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted). |
Alzheimer's disease study 9 / normal pyramidal neuron (posterior cingulate)
Relative Expression (log2-ratio):-1.8418121Number of Samples:9 / 13
| Experimental | Alzheimer's disease study 9 |
| Cortical layer III pyramidal neurons of the posterior cingulate of clinically and neuropathologically classified late-onset Alzheimer´s disease afflicted individuals. Subjects in this group had a Braak stage of V or VI with a CERAD score of moderate or frequent. | |
| Control | normal pyramidal neuron (posterior cingulate) |
| Cortical layer III pyramidal neurons of the posterior cingulate of clinically classified as neurologically normal individuals. Subjects in this group had a Braak stage ranging from I to II with a infrequent Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuritic plaque density. |
oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample
Relative Expression (log2-ratio):-1.7729712Number of Samples:3 / 3
| Experimental | oncolytic herpes simplex virus study 2 |
| Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours. | |
| Control | mock infected peripheral nerve sheath tumor (S462) cell sample |
| Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours. |
endometriosis study 6 (minimal/mild endo.; pro. MCP) / normal endometrium tissue (pro. MCP)
Relative Expression (log2-ratio):-1.7205057Number of Samples:12 / 20
| Experimental | endometriosis study 6 (minimal/mild endo.; pro. MCP) |
| Endometrial tissue samples from women with minimal or mild endometriosis and pelvic pain and/or infertility collected in the proliferative menstrual cycle phase (MCP). Endometriosis was diagnosed based on the revised American Fertility Society classification system. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded. | |
| Control | normal endometrium tissue (pro. MCP) |
| Normal endometrial tissue samples from women collected in the proliferative menstrual cycle phase (MCP). The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. |
F. tularensis study 1 (novicida) / uninfected peripheral blood monocyte sample
Relative Expression (log2-ratio):-1.7169714Number of Samples:4 / 6
| Experimental | F. tularensis study 1 (novicida) |
| Peripheral blood monocytes infected with the Francisella tularensis subspecies novicida isolate U112 (100 MOI) for 24 hours. | |
| Control | uninfected peripheral blood monocyte sample |
| Peripheral blood monocytes uninfected. |
expO breast cancer study 1 (papillary carcinoma, NOS; primary) / expO breast cancer study 1 (inflammatory carcinoma; primary)
Relative Expression (log2-ratio):1.7160721Number of Samples:2 / 2
| Experimental | expO breast cancer study 1 (papillary carcinoma, NOS; primary) |
| Primary tumor tissue samples obtained from the breast of patients with papillary carcinoma (NOS). | |
| Control | expO breast cancer study 1 (inflammatory carcinoma; primary) |
| Primary tumor tissue samples obtained from the breast of patients with inflammatory carcinoma. |
ovarian tumor study 16 / normal ovarian surface epithelial cell sample
Relative Expression (log2-ratio):-1.6654186Number of Samples:3 / 5
| Experimental | ovarian tumor study 16 |
| Human epithelial tumor cell samples from the ovary of patients with papillary serous carcinoma. Samples were derived by laser capture microdissection (LCM). | |
| Control | normal ovarian surface epithelial cell sample |
| Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue. |
expO breast cancer study 1 (papillary carcinoma, NOS; primary) / expO breast cancer study 1 (adenocarcinoma with squamous metaplasia; primary)
Relative Expression (log2-ratio):1.6084328Number of Samples:2 / 2
| Experimental | expO breast cancer study 1 (papillary carcinoma, NOS; primary) |
| Primary tumor tissue samples obtained from the breast of patients with papillary carcinoma (NOS). | |
| Control | expO breast cancer study 1 (adenocarcinoma with squamous metaplasia; primary) |
| Primary tumor tissue samples obtained from the breast of patients with adenocarcinoma with squamous metaplasia. |
expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic) / expO ovary cancer study 1 (mucinous adenocarcinoma; metastatic)
Relative Expression (log2-ratio):-1.5746565Number of Samples:8 / 2
| Experimental | expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary serous cystadenocarcinoma (NOS) of the ovary. | |
| Control | expO ovary cancer study 1 (mucinous adenocarcinoma; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary mucinous adenocarcinoma of the ovary. |
expO ovary cancer study 1 (transitional cell carcinoma, NOS; primary) / expO ovary cancer study 1 (mucinous adenocarcinoma; primary)
Relative Expression (log2-ratio):-1.5072432Number of Samples:2 / 6
| Experimental | expO ovary cancer study 1 (transitional cell carcinoma, NOS; primary) |
| Primary tumor tissue samples obtained from the ovary of patients with transitional cell carcinoma (NOS). | |
| Control | expO ovary cancer study 1 (mucinous adenocarcinoma; primary) |
| Primary tumor tissue samples obtained from the ovary of patients with mucinous adenocarcinoma. |